Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the role of secondary cytoreduction (SCR) and
validate the risk model of patient selection criteria in platinum-sensitive recurrent ovarian
cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Gynecologic Oncology Group
Collaborators:
Fudan University Shanghai Zhongshan Hospital Sun Yat-sen University Zhejiang Cancer Hospital